Harrow, Inc. (HROW) Fair Value 2026

HROW · Drug Manufacturers - Specialty & Generic ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

7.0 /10

32 fundamental signals · 7 models active

Value Trap Risk

SAFE (13/100)

Quick Summary — As of 2026-08-27, Harrow, Inc. (HROW) trades at $38.54, versus a $8.88 median fair value across its 7 active models — 76.9% below the current price. QOC: 7.0/10. Value Trap Risk: 13/100 (SAFE). 7/13 models active.

Key Facts

Ticker
HROW
Price
$38.54
Quality Score
7.0/10
Value Trap Risk
13/100
Models Active
7/13
Last Updated
Strength: 7 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

Is Harrow, Inc. (HROW) Undervalued or Overvalued in 2026?

According to CirclFi’s 7-model valuation engine, Harrow, Inc. (HROW) appears overvalued as of : the median of 7 independent fair value estimates is $8.88, 76.9% below the current price of $38.54. Estimates range from $2.82 to $60.77. HROW scores 7.0/10 on fundamental quality and 13/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. HROW’s -76.9% gap is wider than that market norm, and the Drug Manufacturers - Specialty & Generic sector median is -1.4%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Harrow, Inc. Stock in 2026? →

What Fair Value Does Each Model Give HROW?

7 Intrinsic Value Models vs. Current Price ($38.54)

Core Models (Unlocked)
Model Fair Value Upside
Ensemble · Low Conviction
 $8.88 -76.9%
Scenario · High Conviction
 $9.50 -75.3%
Intrinsic · High Conviction
 $4.61 -88.0%
Unlock the Full Matrix

Access 4 additional models including Regime Cross-Sectional, Sentiment SOTP, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 7 Models →

Cancel anytime · No contracts · Instant access

What Is HROW's Fair Value Range?

Spread across 7 independent models · $2.82 to $60.77

CirclFi's 7 active models place Harrow, Inc. (HROW) between $2.82 and $60.77 per share, a spread of 652% of the median. The median of that range — $8.88 — is the fair value CirclFi publishes for HROW, against a current price of $38.54.

Low · Sentiment SOTPHigh · Regime Cross
$2.82median $8.88$60.77
Where the range comes from
Most bearish modelSentiment SOTP$2.82
Most bullish modelRegime Cross-Sectional$60.77
Model agreement1 bullish · 6 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for HROW. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on HROW, not a CirclFi price target. How each model works →

What Is Harrow, Inc. (HROW) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Harrow, Inc.'s intrinsic value is estimated at $8.88. Trading at its current price of $38.54, the valuation engine raises significant caution: 6 of 7 models flag downside risk, projecting a median implied return of -76.9%. Model dispersion is worth noting: Regime Cross targets $60.77 (+57.7%), versus Sentiment SOTP at $2.82 (-92.7%). This +150.4% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About HROW?

7 of 13 models are currently active for HROW. Of these, 1 model suggests upside while 6 models suggest overvaluation. Taken together, their median fair value for HROW is $8.88 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does HROW Rank in Drug Manufacturers - Specialty & Generic?

Among 110 Drug Manufacturers - Specialty & Generic stocks, HROW ranks #33 by Quality of Company score. CirclFi's QOC score of 7.0/10 evaluates 32 fundamental signals. A score of 7.0 indicates above-average quality.

See all Most Undervalued Drug Manufacturers - Specialty & Generic Stocks →

The Drug Manufacturers - Specialty & Generic sector introduces analytical considerations specific to biopharma enterprise businesses. For Harrow, Inc., metrics like FDA approval probability provide important context that general-purpose valuation models may underweight.

Is HROW a Value Trap?

CirclFi's Value Trap algorithm assigns HROW a score of 13/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

7 of 13 models are active for Harrow, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Harrow, Inc. scores 7.0 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

The gap between the most bullish and bearish model spans +150.4% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every HROW valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across HROW's 7 active models, average confidence is 43%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Harrow, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - Specialty & Generic Stocks Should You Also Analyze?

11 related Drug Manufacturers - Specialty & Generic stocks with 13-model coverage

TAKTakeda Pharmaceutical Company LimitedQOC 7.0BHCBausch Health Companies Inc.QOC 6.8LQDALiquidia CorporationQOC 7.0MRMDMariMed Inc.QOC 6.8EBSEmergent BioSolutions Inc.QOC 7.1ANIKAnika Therapeutics, Inc.QOC 6.8TLRYTilray Brands, Inc.QOC 5.9CPMDCannaPharmaRX, Inc.QOC 4.6NBIXNeurocrine Biosciences, Inc.QOC 9.1UTHRUnited Therapeutics CorporationQOC 9.6AMPHAmphastar Pharmaceuticals, Inc.QOC 9.4

Read investment analysis: TAK · BHC · LQDA · MRMD · EBS · ANIK · TLRY · CPMD · NBIX · UTHR · AMPH

Which Other Stocks Have a Similar Quality Score to HROW?

7 companies across all industries closest to HROW’s Quality of Company score of 7.0/10.

ANABAnaptysBio, Inc.QOC 7.0WHRWhirlpool CorporationQOC 7.0YRDYiren Digital Ltd.QOC 7.0PRTAProthena Corporation plcQOC 7.0OCCOptical Cable CorporationQOC 7.0DCODucommun IncorporatedQOC 7.0NVDANVIDIA CorporationQOC 10.0

Read investment analysis: ANAB · WHR · YRD · PRTA · OCC · DCO · NVDA

Where Does HROW Sit in CirclFi's Drug Manufacturers - Specialty & Generic Rankings?

HROW is ranked against every other Drug Manufacturers - Specialty & Generic stock CirclFi covers in each of these screens.

See all Drug Manufacturers - Specialty & Generic stocks ranked →

What Else Do Investors Ask About Harrow, Inc.’s Valuation?

What is Harrow, Inc.'s intrinsic value in 2026?

CirclFi puts Harrow, Inc. (HROW)'s intrinsic value at $8.88 — the median of 7 independent model estimates as of 2026-08-27, ranging from $2.82 to $60.77. The Quality of Company score is 7.0/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is HROW overvalued or undervalued right now?

At $38.54, 1 of 7 active models suggest HROW may be undervalued, while 6 indicate potential overvaluation. The median of all 7 fair value estimates is $8.88, 76.9% below the current price of $38.54 — a consensus view that HROW is overvalued. The assessment depends on which methodology best fits Harrow, Inc.'s business model in Drug Manufacturers - Specialty & Generic.

What does a Quality of Company score of 7.0 mean for HROW?

Harrow, Inc.'s QOC of 7.0/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on HROW?

CirclFi analyzes HROW with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 7 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on HROW?

Of the 7 models currently active on HROW, Regime Cross-Sectional is the most bullish at $60.77 per share, and Sentiment SOTP is the most bearish at $2.82. CirclFi's published fair value for HROW is the median of that range, $8.88, not either extreme. The gap between the two ends equals 652% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is HROW a value trap in 2026?

Harrow, Inc.'s Value Trap score is 13/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 7-model valuation engine, Harrow, Inc. (HROW) has a median fair value of $8.88 — 76.9% below the current price of $38.54 — as of 2026-08-27.” Source: circlfi.com/stock/HROW/ · Methodology
Primary sources for this HROW valuation
  • Financial statements: Harrow, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001360214) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for HROW as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 7 mathematical frameworks give you clarity on HROW.

Unlock All 7 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

4 models hidden for HROW Unlock All 7 — $39/mo